CRA was retained by the claimant in an arbitration regarding the breach of a license agreement relating to pharmaceutical manufacturing technology. In addition to quantifying damages, the CRA team also provided opinions relating to the value of market exclusivity for pharmaceuticals and the relative value of the licensed patented and non-patented intellectual property at issue in the case. Dr. Sean Sheridan submitted two expert reports and provided testimony in deposition and at the arbitration hearing.
Smallest saleable patent-practicing unit in life sciences disputes
In this article titled “Smallest saleable patent-practicing unit in life sciences disputes,” author Erin McDermott examines methods for calculating damages in...